NOV 11

Commercial Launch of Fortacin™ a Breakthrough Treatment for Premature Ejaculation Now Available in the UK and, from 2017, in Continental Europe

AUG 30

Regent Pacific Announces 2016 Interim Financial Results Substantial Increase in Profits and Shareholder Equity

MAY 16

Regent Pacific Secures Variation Approval for Commercial Launch of the Reduced Dose Can Version of its Premature Ejaculation Treatment PSD502®

APR 20

Regent Pacific further invests up to GBP 3 million in The Diabetic Boot Company Limited, increasing its stake initially to 23.0% and potentially up to 33.1%

APR 18

Regent Pacific’s Premature Ejaculation Treatment PSD502® Enters Final Stage of Commercialisation

MAR 10

Regent Pacific Announces Successful Acquisition of London AIM listed Plethora Solutions Holdings Plc Transition into a Hong Kong Listed Healthcare Investment Vehicle